Jacqueline Marino

关于 Jacqueline Marino

Jackie focuses on advising corporate clients and financial institutions on a variety of public and private capital markets transactions, including IPOs and other equity offerings, investment grade, high-yield and convertible debt financings, private placements and liability management transactions. She also regularly represents clients on general corporate, SEC compliance, disclosure and corporate governance matters.

近期项目经验

IPOs

• Arm’s $5.23bn IPO and listing on Nasdaq
• Kenvue’s $4.37bn carve-out IPO and listing on the NYSE
• Allegro MicroSystems’ $402.5m IPO and listing on Nasdaq
• Royalty Pharma’s $2.5bn IPO and listing on Nasdaq Global Select Market
• Pactiv Evergreen’s $574m IPO and listing on Nasdaq Global Select Market
• Reynolds Consumer Products’ $1.4bn IPO and listing on Nasdaq Global Select Market
• Oportun Financial Corporation’s $100.3m IPO and listing on Nasdaq Global Select Market
• TransMedics Group’s $104.7m IPO and listing on Nasdaq Global Select Market
• Gates Industrial Corporation’s $731.6m IPO and listing on NYSE

Debt Offerings

• Rapid7‘s $260m Rule 144A offering of convertible notes
• Polaris’ $500m SEC-registered offering of investment grade notes
• Madison Dearborn Partners’ $1.05bn MoneyGram acquisition financing comprised of a $400m senior secured term loan facility, $150m senior secured revolving credit facility and $500m Rule 144A / Reg S offering of senior secured notes
• Kenvue’s $7.75bn Rule 144A / Reg S offering of investment grade notes
• Frontier Communications’ multiple Rule 144A / Reg S offerings of high yield notes
• Ormat Technologies’ $375m convertible senior notes offering
• Rocket Mortgage’s $1.15 Rule 144A / Reg S offering of high yield notes
• Pactiv Evergreen’s multiple Rule 144A / Reg S offerings of high yield notes
• Adtalem Escrow Corporation’s $800m Rule 144A / Reg S offering of notes
• Seagate Technology’s multiple Rule 144A / Reg S offerings of high yield notes
• Royalty Pharma’s $6bn Rule 144A / Reg S investment grade notes
• Intercontinental Exchange’s $6.5bn SEC-registered offering of investment grade notes
• Graham Packaging Company’s $510m Rule 144A / Reg S high yield notes
• Black Hills Corporation’s multiple SEC-registered notes offerings
• Fiserv’s $2bn SEC-registered offering of investment grade notes
• Campbell Soup Company’s $1bn SEC-registered offering of investment grade notes
• MSCI’s multiple Rule 144A / Reg S offerings of high yield notes
• Ascend Learning’s $350m Rule 144A / Reg S offering of high yield notes
• Electronics for Imaging’s $150m Rule 144A offering of convertible notes
• Hilton Worldwide Holdings’ $1.5bn Rule 144A / Reg S offering of high yield notes
• Valeant Pharmaceuticals’ multiple Rule 144A / Reg S offerings of high yield notes
• Ensco’s $1bn SEC-registered offering of investment grade notes
• Schlumberger Limited’s $1.1bn Rule 144A / Reg S offering of high yield notes
• Suncor Energy’s $750m SEC-registered offering of investment grade notes

Equity Offerings

• Kenvue’s $3.7bn debt for equity exchange and secondary offering
• Portland General Electric’s $300 million at-the-market offering listed on the NYSE (counsel to the agents and forward purchasers)
• Ormat Technologies’ multiple primary and secondary public offerings of common stock
• Portland General Electric’s SEC-registered offering of common stock and concurrent execution of forward sale agreements
• Oak Street Health’s $180.3m secondary offering
• Hayward Holdings’ $348m secondary offering
• Perion Network’s $180m follow-on offering
• Merchants Bancorp’s $98m SEC-registered offering of common stock
• Hamilton Lane’s $80m follow-on offering of common stock
• Seer’s $251.3m follow-on offering of common stock
• Open Lending’s $305.9m secondary offering of common stock
• Royalty Parma’s $728m secondary offering of ordinary shares
• Humanigen’s $72m Rule 4(a)(2) private placement
• Black Hills’ $100m SEC-registered primary block trade
• Stemline Therapeutics’ $88m follow-on offering of common stock
• NeoGenomics’ $171m follow-on offering of common stock
• Hilton’s $4.8bn secondary offering of common stock
• General Motors’ $1.59bn secondary offering of common stock
• Webster Financial’s $146m offering of depository shares

Liability Management Transactions

• Pactiv Evergreen’s multiple tender offers to purchase certain series of its outstanding bonds
• Valaris’ consent solicitation for certain outstanding bonds
• Rocket Mortgage’s cash tender offer and related consent solicitation for certain of its outstanding bonds
• Genworth Holdings’ consent solicitation for certain outstanding bonds
• Ensco’s cash tender offer for certain outstanding bonds

Additional Transactions

• Johnson & Johnson’s $33bn split-off exchange offer to exchange shares of Kenvue common stock for outstanding shares of Johnson & Johnson common stock
• Kenvue’s $4bn commercial paper program
• Aetna’s $200m reinsurance transaction, including a $140m private placement of Class A variable rate notes and $60m Class B variable rate notes